



pharma& to Highlight Long-Term Data for Rubraca® (rucaparib) in Advanced Ovarian Cancer at 2025 ESGO Annual Congress

Intended for the healthcare media

Vienna, Austria, February 6, 2025 – pharmaand GmbH (pharma&), a global company dedicated to preserving the availability and fostering the further development of essential medicines to leave no patient behind, today announced long-term data for rucaparib in advanced ovarian cancer will be presented in a poster session during the European Society of Gynecological Oncology (ESGO) Annual Congress Feb. 20 – 22 in Rome, Italy.

Abstract No. 573: ATHENA-MONO Post-Progression Survival Data Update in Patients With Newly Diagnosed Advanced Ovarian Cancer.

Presenter and Lead Author: Dr. Sharad Ghamande, Georgia Cancer Center, Augusta University, Augusta, GA

Date and Time: Friday, Feb. 21, 1:05 p.m. – 1:50 p.m.

Poster Session: Group A

Location: Exhibition Hall

pharma& has also organized and funded a medical symposium, "PARPi: New Horizons for Patients With Advanced Ovarian Cancer. Bringing Evidence To Patient Care."

Presenters:

- Prof. Bradley Monk (Chair), GOG Foundation, Florida Cancer Specialists & Research Institute, West Palm Beach, FL
- Dr. Rebecca Kristeleit, Guy's and St Thomas' NHS Foundation Trust, London UK
- Prof. Iain McNeish, Imperial College London, London, UK
- Prof. Domenica Lorusso, Humanitas Hospital San Pio X, Humanitas University, Milan, Italy

Date and Time: Friday, Feb. 21, 11 a.m. - 12 p.m.

Location: Hall 3

Attendees can visit pharma& at its booth, E02, near meeting hall 1.

###

About pharma& (pharmaand.com)

pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines through an agile and fully integrated business model, and aims to guarantee the enduring availability, dependability, and quality of essential drugs worldwide that patients and healthcare providers rely on. Over the past five years, pharma& has acquired and integrated 10+ medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of development, product and API manufacturing, partner distribution, healthcare provider engagement, distribution, and services to patients.

#

pharma& Media Contact:

media@pharmaand.com